Literature DB >> 28532005

Non-viral strategies for ocular gene delivery.

Ana V Oliveira1, Ana M Rosa da Costa2, Gabriela A Silva3.   

Abstract

The success of gene therapy relies on efficient gene transfer and stable transgene expression. The in vivo efficiency is determined by the delivery vector, route of administration, therapeutic gene, and target cells. While some requirements are common to several strategies, others depend on the target disease and transgene product. Consequently, it is unlikely that a single system is suitable for all applications. This review examines current gene therapy strategies, focusing on non-viral approaches and the use of natural polymers with the eye, and particularly the retina, as their gene delivery target.
Copyright © 2017 Elsevier B.V. All rights reserved.

Keywords:  Eye; Gene therapy; Non-viral vectors; Retina

Mesh:

Year:  2017        PMID: 28532005     DOI: 10.1016/j.msec.2017.04.068

Source DB:  PubMed          Journal:  Mater Sci Eng C Mater Biol Appl        ISSN: 0928-4931            Impact factor:   7.328


  15 in total

1.  A combinatorial library of biodegradable polyesters enables non-viral gene delivery to post-mitotic human stem cell-derived polarized RPE monolayers.

Authors:  Bibhudatta Mishra; David R Wilson; Srinivas R Sripathi; Mark P Suprenant; Yuan Rui; Karl J Wahlin; Cynthia A Berlinicke; Jordan J Green; Donald J Zack
Journal:  Regen Eng Transl Med       Date:  2019-07-24

2.  Lipid nanoparticles for delivery of messenger RNA to the back of the eye.

Authors:  Siddharth Patel; Renee C Ryals; Kyle K Weller; Mark E Pennesi; Gaurav Sahay
Journal:  J Control Release       Date:  2019-04-12       Impact factor: 9.776

3.  Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy.

Authors:  Andrea E Dillinger; Michaela Guter; Franziska Froemel; Gregor R Weber; Kristin Perkumas; W Daniel Stamer; Andreas Ohlmann; Rudolf Fuchshofer; Miriam Breunig
Journal:  Small       Date:  2018-10-23       Impact factor: 13.281

4.  Effects of spinal non-viral interleukin-10 gene therapy formulated with d-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues.

Authors:  Arden G Vanderwall; Shahani Noor; Melody S Sun; Jacob E Sanchez; Xuexian O Yang; Lauren L Jantzie; Nikolaos Mellios; Erin D Milligan
Journal:  Brain Behav Immun       Date:  2017-11-04       Impact factor: 7.217

Review 5.  Principles of pharmacology in the eye.

Authors:  Sahar Awwad; Abeer H A Mohamed Ahmed; Garima Sharma; Jacob S Heng; Peng T Khaw; Steve Brocchini; Alastair Lockwood
Journal:  Br J Pharmacol       Date:  2017-10-10       Impact factor: 8.739

6.  In Vitro Evaluation of Lipopolyplexes for Gene Transfection: Comparing 2D, 3D and Microdroplet-Enabled Cell Culture.

Authors:  Juan L Paris; Filipe Coelho; Alexandra Teixeira; Lorena Diéguez; Bruno F B Silva; Sara Abalde-Cela
Journal:  Molecules       Date:  2020-07-18       Impact factor: 4.411

Review 7.  Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management.

Authors:  Arden G Vanderwall; Erin D Milligan
Journal:  Front Immunol       Date:  2019-12-23       Impact factor: 7.561

8.  A method for gene knockdown in the retina using a lipid-based carrier.

Authors:  Joshua A Chu-Tan; Nilisha Fernando; Riemke Aggio-Bruce; Adrian V Cioanca; Krisztina Valter; Nektaria Andronikou; Xavier deMollerat du Jeu; Matt Rutar; Jan Provis; Riccardo Natoli
Journal:  Mol Vis       Date:  2020-02-24       Impact factor: 2.367

9.  Controlled Release of rAAV Vectors from APMA-Functionalized Contact Lenses for Corneal Gene Therapy.

Authors:  Fernando Alvarez-Rivera; Ana Rey-Rico; Jagadeesh K Venkatesan; Luis Diaz-Gomez; Magali Cucchiarini; Angel Concheiro; Carmen Alvarez-Lorenzo
Journal:  Pharmaceutics       Date:  2020-04-09       Impact factor: 6.321

10.  Exosome-associated SUMOylation mutant AAV demonstrates improved ocular gene transfer efficiency in vivo.

Authors:  Shubham Maurya; Giridhara R Jayandharan
Journal:  Virus Res       Date:  2020-04-14       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.